Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints.
(2020) Kidney International Reports — Vol. 5, n° 8, p. 1302-1305 (2020)
Files
2020_Almaani_Kidney_Int_Rep.pdf
Open Access - Adobe PDF
- 600.45 KB
Details
- Authors
- Abstract
- Lupus nephritis (LN) is a common manifestation of systemic lupus erythematosus (SLE) and a major driver of morbidity and mortality. Proliferative forms of LN are typically managed with immunosuppressive therapy, with the aim of attenuating renal inflammation and preserving kidney function.1 Unfortunately, despite several clinical trials of LN conducted over the past 30 to 40 years, none has translated into new Food and Drug Administration (FDA)−approved therapies. Multiple issues in clinical trial design likely contributed to these negative outcomes, such as confounding background medications (especially high-dose glucocorticoids), trial duration, and the choice of trial endpoints. Most trials incorporated composite endpoints to define clinical response based on proteinuria and kidney function. Kidney function was generally assessed as a change in estimated glomerular filtration rate or serum creatinine (sCr) as compared to the patients’ values at trial entry.2 Thresholds were then chosen to define the extent of the clinical response (complete, partial, or no response). However, evidence supporting these thresholds is not robust. For example, most studies used a proteinuria cutoff of <0.3 to 0.5 g/d to describe complete response; however, a post hoc analysis of 2 large LN trials demonstrated that proteinuria levels of <0.7 to 0.8 g/d after 1 year of treatment predicted favorable long-term kidney outcomes, suggesting that a less stringent proteinuria cutoff may be reasonable. Similarly, an sCr value <15% above baseline has often been required for complete response in LN trials.S1−S5 However, day-to-day variations in sCr measurements are routinely observed in clinical practice in patients with and without chronic kidney disease, even when measured within a 24-hour period.3 To determine a threshold of kidney function that accounts for expected day-to-day variations, we investigated the fluctuation of sCr in a cohort of patients with LN who were complete renal responders. [...]
- Affiliations
Citations
Almaani, S., Bhatt, U., Arriens, C., Bonfa, E., Dall’Era, M., Houssiau, F., Kalunian, K., Mackay, M., Sanchez-Guerrero, J., Solomons, N., & Rovin, B. H. (2020). Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints. Kidney International Reports, 5(8), 1302-1305. https://doi.org/10.1016/j.ekir.2020.05.011 (Original work published 2020)